Loading...
XSHG
688393
, Last price  
Name

Guangzhou LBP Medicine Science & Technology Co Ltd

Chart & performance

D1W1MN
XSHG:688393 chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
3.80%
Rev. 5Y
-1.83%
Div Yld LY
—
Div Yld TTM
—
Revenues
342m
-27.30%
87,718,900107,445,800142,600,600241,160,419260,469,660306,296,199355,159,969375,433,110438,988,843507,381,222497,290,537470,790,075342,245,540
Net income
-47m
L
27,150,00027,734,30038,431,30046,028,69248,338,74961,471,78073,988,89984,745,71379,775,77442,694,28440,057,21321,291,314-47,023,428
CFO
58m
+1,536.21%
-15,244,6004,836,100-696,70043,373,94483,918,53365,351,37489,739,04591,425,99359,614,4449,716,44117,121,3013,543,28757,975,724
Dividend
Jun 03, 20260.1 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangzhou LBP Medicine Science & Technology Co., Ltd. specializes in the development and manufacture of innovative pathological diagnostic solutions for the Chinese market. Its comprehensive product portfolio includes advanced pathological diagnostic reagents and essential ancillary equipment. Among these are liquid-based cytology (LBC) offerings, encompassing both gynecological and non-gynecological series, complemented by specialized equipment. The company also provides fluorescence in situ hybridization (FISH) products, which are applied across a broad spectrum of conditions. These applications range from various cancers, including breast, bladder, lung, cervical, prostate, and thyroid, to other complex diagnoses such as neuroblastoma, soft tissue sarcoma, diverse solid tumors, prenatal screening, complications in abortion, oligodendrocytes tumors, lymphoma, multiple myeloma, and several forms of leukemia (chronic myelogenous, chronic lymphocytic, acute myeloid, and acute lymphoblastic), as well as myelodysplastic syndromes. Furthermore, GLBP offers immunohistochemistry (IHC) products, comprising a range of antibodies, advanced detection and repair systems, complementary products, and complete IHC kits. Additionally, its capabilities extend to molecular genetic diagnosis products. Established in 2005, Guangzhou LBP Medicine Science & Technology Co., Ltd. is headquartered in Guangzhou, China.
IPO date
Aug 20, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT